KPMG Australia Cuts 5% of Workforce Amid Scandal 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Nvidia Options Price in $280 Billion Earnings Swing 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Trump Buys SpaceX Shares After Record IPO 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Add as a preferred source on Google
LAKE FOREST, Ill., May 03, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first-quarter 2018 financial results on Thursday, May 10, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results.
Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
Audio Conference Call:
| U.S. Dial-in Number: | 1-877-326-2337 |
| International Dial-in Number: | 1-631-456-4258 |
| Conference ID: | 1328285277 |
An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
John B. Thomas
SVP, Investor Relations and Corporate Communications
[email protected]
